Haegarda
Biological
CSL Behring
Total Payments
$9.6M
Transactions
35,068
Doctors
5,099
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $292,879 | 5,815 | 2,040 |
| 2023 | $258,975 | 5,071 | 1,702 |
| 2022 | $576,803 | 4,663 | 1,676 |
| 2021 | $820,773 | 5,462 | 1,590 |
| 2020 | $1.1M | 3,421 | 1,073 |
| 2019 | $607,589 | 4,458 | 1,428 |
| 2018 | $1.0M | 3,385 | 1,091 |
| 2017 | $5.0M | 2,793 | 1,024 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.7M | 571 | 59.5% |
| Honoraria | $2.0M | 1,075 | 21.2% |
| Food and Beverage | $766,817 | 30,822 | 8.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $616,946 | 232 | 6.4% |
| Travel and Lodging | $409,342 | 1,123 | 4.3% |
| Consulting Fee | $24,810 | 10 | 0.3% |
| Grant | $20,000 | 1 | 0.2% |
| Education | $15,613 | 1,234 | 0.2% |
Payments by Type
Research
$5.7M
571 transactions
General
$3.9M
34,497 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema | CSL Behring | $4.1M | 2 |
| A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients | CSL Behring | $1.3M | 0 |
| Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients | CSL Behring | $384,549 | 0 |
| Retrospective Analysis of Patient Outcomes Associated with Subcutaneous C1INH Prophylaxis for HAE | CSL Behring | $6,200 | 0 |
Top Doctors Receiving Payments for Haegarda
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Birmingham, AL | $5.5M | 646 |
| , M.D | Pediatric Allergy/Immunology | Santa Monica, CA | $427,864 | 452 |
| , MD | Allergy & Immunology | Cleveland, OH | $295,490 | 284 |
| , M.D | Specialist | Dallas, TX | $233,817 | 152 |
| , MD | Allergy & Immunology | Orange, CA | $231,241 | 191 |
| , MD, PHD | Allergy | Wheaton, MD | $196,943 | 242 |
| , MD | Allergy & Immunology | Washington, DC | $164,839 | 282 |
| , MD | Allergy & Immunology | Los Angeles, CA | $132,347 | 113 |
| , MD | Allergy & Immunology | Scottsdale, AZ | $124,982 | 155 |
| , M.D., | Allergy | Bloomingdale, IL | $112,991 | 202 |
| , MD | Allergy & Immunology | Tulsa, OK | $112,812 | 206 |
| Ellen Pratt | Allergy & Immunology | Springfield, IL | $109,258 | 172 |
| , M.D | Student in an Organized Health Care Education/Training Program | Homewood, AL | $98,830 | 186 |
| , DO | Allergy & Immunology | Hershey, PA | $89,473 | 97 |
| , DO | Allergy & Immunology | Charlotte, NC | $87,233 | 109 |
| , MD | Allergy | Fair Lawn, NJ | $85,585 | 133 |
| , MD | Internal Medicine | Cincinnati, OH | $75,795 | 63 |
| , M.D | Internal Medicine | San Diego, CA | $45,433 | 57 |
| , M.D.M.D | Allergy & Immunology | North Charleston, SC | $38,191 | 53 |
| , MD | Allergy & Immunology | Saint Louis, MO | $37,351 | 40 |
| , MD | Allergy & Immunology | Woodbury, NJ | $32,227 | 60 |
| , MD | Allergy & Immunology | Charlotte, NC | $30,607 | 108 |
| , MD | Allergy & Immunology | Columbus, OH | $30,495 | 39 |
| , MD | Internal Medicine | Murray, UT | $26,357 | 59 |
| , MD | Allergy & Immunology | Spokane, WA | $25,685 | 29 |
Ad
Manufacturing Companies
- CSL Behring $9.6M
Product Information
- Type Biological
- Total Payments $9.6M
- Total Doctors 5,099
- Transactions 35,068
About Haegarda
Haegarda is a biological associated with $9.6M in payments to 5,099 healthcare providers, recorded across 35,068 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2017 to 2024. In 2024, $292,879 was paid across 5,815 transactions to 2,040 doctors.
The most common payment nature for Haegarda is "Unspecified" ($5.7M, 59.5% of total).
Haegarda is associated with 4 research studies, including "A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema" ($4.1M).